Successful Treatment of Severe Heparin-induced Thrombocytopenia with Intravenous Immunoglobulin, Platelet Transfusion and Rivaroxaban: A Case Report

Heparin-induced thrombocytopenia(HIT) is a relatively infrequent complication of heparin administration. HIT can cause devastating thrombosis, making it one of the most serious adverse drug reactions encountered in clinical practice. We successfully treated a case of severe HIT presenting with thrombosis and life-threatening bleeding complications with intravenous immunoglobulin(IVIG), platelet transfusion and oral anticoagulant Rivaroxaban. In this case, we considered that IVIG played the most important role by preventing further thrombosis, increasing the platelet count, and ensuring the efficacy of Rivaroxaban. We therefore suggest that IVIG might be the optimal treatment for patients with this urgent condition.

Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation

Shortage of appropriate donor grafts is the foremost current problem in organ transplantation. As a logical consequence, waiting times have extended and pretransplant mortality rates were significantly increasing. The implementation of a priority-based liver allocation system using the model of end-stage liverdisease(MELD) score helped to reduce waiting list mortality in liver transplantation(LT). However, due to an escalating organ scarcity, pre-LT MELD scores have significantly increased and liver recipients became more complex in recent years. This has finally led to posttransplant decreasing survival rates, attributed mainly to elevated rates of infectious and immunologic complications. To meet this challenging development, an increasing number of extended criteria donor grafts are currently accepted, which may, however, aggravate the patients' infectious and immunologic risk profiles. The administration of intravenous immunoglobulins(IVIg) is an established treatment in patients with immune deficiencies and other antibody-mediated diseases. In addition, IVIg was shown to be useful in treatment of several disorders caused by deterioration of the cellular immune system. It proved to be effective in preventing hyperacute rejection in highly sensitized kidney and heart transplants. In the liver transplant setting, the administration of specific Ig against hepatitis B virus is current standard in post-LT antiviral prophylaxis. The mechanisms of action of IVIg are complex and not fully understood. However, there is increasing experimental and clinical evidence that IVIg has an immuno-balancing impact by a combination of immuno-supporting and immuno-suppressive properties. It may be suggested that, especially in the context of a worsening organ shortage with all resulting clinical implications, liver transplant patients should benefit from immuno-regulatory capabilities of IVIg. In this review, perspectives of immune modulation by IVIg and impact on outcome in liver transplant patients are described.

Correlation of IL-1, IL-6, IL-10 Concentrations to Ovarian Hyperstimulation Syndrome and Effect of Intravenous Immunoglobulin on Ovarian Hyperstimulated Rats

Objective To investigate the correlation of interleukin（IL）-1,IL-6 and IL-10 concentrations to ovarian hyperstimulation syndrome（OHSS） and whether intravenous immunoglobulin（IVIG） has the effects on ovarian hyperstimulated rats. Methods Immature female Wistar rats were divided into control group, OHSS group （n=13） and IVIG group（n=13）. For the latter two groups, pregnancy mare serum gonadotropin（PMSG）and human chorionic gonadotropin（hCG） were given to induce OHSS, and rats in IVIG group were treated with immunoglobulin. Forty-eight hours after administration of hCG, capillary permeability was evaluated from the Evans blue dye（EB） concentration in the ovaries and the EB concentration in peritoneal irrigated fluid at 30 min after the intravenous injection of EB. Rats＇ blood samples and ovaries were obtained to be measured for IL-1, IL-6 and IL-10 by ELISA. Results In OHSS group, total weights of bilateral ovaries and the ovarian EB concentration were significantly higher than those in others（P〈0.05）. Both serum and ovarian concentrations of IL-1 were significantly higher in OHSS and IVIG groups than those in control group （P〈0.05）. The ovarian concentrations of IL-6 and IL-10 in IVIG group were significantly lower than those in control group（P〈0.05）. Furthermore, the ovarian IL-10 concentration in IVIG group was significantly lower than that in OHSS group（P〈0. 05）. Conclusion Inflammation involved IL-1 in OHSS rats plays an important role. Vascular permeability was mostly increased in ovaries of hyperstimulated rats. It appears that ovaries of OHSS rats may be the primary places of inflammation. IVIG treatment resulted in statistically significant reductions in ovaries＇ weights and ovarian vascular permeability of OHSS rats, with a decreased level of ovarian IL-10. It implys that IVIG have a beneficial effect in reducing the severity of OHSS in the experimental model maybe by restrainning IL-10.

A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure

BACKGROUND： The established procedure for ABO-incompatible liver transplantation（ABO-I LT） was too complicated to be used in case of emergency. We developed a protocol consisting of rituximab and intravenous immunoglobulin（IVIG） for ABO-I LT in patients with acute liver failure（ALF）.METHODS： The data from 101 patients who had undergone liver transplantation（LT） for ALF were retrospectively analyzed.The patients were divided into two groups： ABO-compatible liver transplantation group（ABO-C LT, n=66） and ABO-I LT group（n=35）. All the patients in the ABO-I LT group received a single dose of rituximab（375 mg/m2） and IVIG（0.4 g/kg per day） at the beginning of the operation. IVIG was administered for 10 consecutive days after LT. Plasma exchange, splenectomy and graft local infusion were omitted in the protocol.Quadruple immunosuppressive therapy including basiliximab,corticosteroids, tacrolimus and mycophenolatemofetil was used to reinforce immunosuppression.RESULTS： The 3-year cumulative patient survival rates in the ABO-I LT and ABO-C LT groups were 83.1% and 86.3%,respectively（P〉0.05）, and the graft survival rates were 80.0%and 86.3%, respectively（P〉0.05）. Two patients（5.7%） suffered from antibody-mediated rejection in the ABO-I LT group.Other complications such as acute cellular rejection, biliary complication and infection displayed no significant differences between the two groups.CONCLUSIONS： The simplified treatment consisting of rituximab and IVIG prevented antibody-mediated rejection for LT of blood-type incompatible patients. With this treatment, the patients did not need plasma exchange, splenectomy and graft local infusion. This treatment was safe and efficient for LT of the patients with ALF.

Budget impact of a 10% ready-to-use intravenous immunoglobulin in the treatment of primary immunodeficiency in Belgium

The aim of this study is to compute the budget impact of adopting Kiovig, a new ready-to-use 10% liquid immunoglobulin preparation, as a treatment for primary immunodeficiency from the perspective of the Belgian health care payer. The analysis compared the “world with Kiovig” to the “world without Kiovig” and calculated how a change in the mix of immunoglobulins used to treat primary immunodeficiency would impact drug spending during 2010-2014. Data on the number of patients, immunoglobulin market shares and drug unit costs were derived from the IMS Health hospital disease database and from Belgian sources. The number of Belgian patients suffering from primary immunodefi-ciency is expected to increase from 2,378 pa-tients in 2010 to 2,447 patients in 2014. The budget impact of adopting Kiovig is likely to be modest, raising the immunoglobulin drug bud- get for this patient population by 0.4%-1.3% per year. The budgetary increase originated from the higher price of Kiovig as compared with other products, although the impact of Kiovig was limited by its anticipated slow market penetra-tion. There is a need for more and better data on the Belgian immunoglobulin market.

A case of Bickerstaff brainstem encephalitis successfully treated with intravenous immunoglobulin and methylprednisolone after unsuccessful immunoadsorption plasmapheresis

Bickerstaff brainstem encephalitis (BBE) is a rare post-infectious neurological syndrome for which an effective treatment strategy has not been established. Here, we report a case of a 71-year-old male who suffered from an upper respiratory tract infection, and 7 days later, developed numbness of the bilateral upper and lower limbs, unsteady gait and dysarthria. Brain magnetic resonance imaging was normal, nerve conduction study and cerebral spinal fluid analysis were nonspecific. Based on the clinical features, we tentatively diagnosed Guillain-Barré syndrome and started immunoadsorption plasmapheresis. However, consciousness progressively declined to coma level within 10 days. Electroencephalogram showed diffuse slowing, and auditory evoked brainstem response (ABR) demonstrated absence of waves II, III and V. Serum anti-GQ1b IgG autoantibody and anti-GM1b IgG autoantibody were negative. Subsequently, we diagnosed BBE, and clinical symptoms resolved after treatment with intravenous immunoglobulin and methyllprednisolone. On day 62, neurological symptoms were remarkably alleviated with an improvement in ABR. Our observations suggest that immunoadsorption plasmapheresis should be used only when anti-ganglioside antibodies are detected. Combination therapy with intravenous immunoglobulin and methylprednisolone or plasma exchange?is recommended as initial therapy.

Role of intravenous immunoglobulin in suspected or proven neonatal sepsis

Neonatal sepsis remains the major cause of mortality and morbidity including neurodevelopmental impairment and prolonged hospital stay in newborn infants. Despite of advances in technology and optimal antibiotic treatment,incidence of neonatal sepsis and its complications remains unacceptably high especially in developing countries. Premature neonates in particular are at higher risk due to developmentally immature host defence mechanisms. Though not approved by Food and Drug Administration(FDA) U. S. A,off label use of intravenous immunoglobulin as prophylactic or adjuvant agent in suspected or proven neonatal infections continues in many countries. In a recent large multicenter clinical trial by International Neonatal Immunotherapy Study(INIS) group, the use of polyvalent IgG immune globulin was not associated with significant differences in the risk of major complications or other adverse outcomes in neonates with suspected or proven sepsis. Hence,use of intravenous immunoglobulin in suspected or proven neonatal sepsis is not recommended. The expense of prophylactic use of intravenous immunoglobulin administration for both term and preterm newborn population,given the minimal benefit as demonstrated by many individual studies and by meta-analysis is not justified.

A Patient with Intravenous Immunoglobulin-Responsive Lower Motor Neuron Syndrome

We report a 50-year-old woman who developed localized proximal muscle weakness, in addition to transient elevation of antibodies to GM-1 ganglioside, without multifocal conduction block. She was treated with intravenous immunoglobulin (IVIg) and steroid pulse therapy, which were effective for over 10 years. Her clinical course and laboratory tests were consistent with lower motor neuron syndrome (LMNS) with localized proximal muscle weakness. We suggest that some patients diagnosed as LMNS may remain responsive to IVIg or steroid pulse therapy for a long time.

Intravenous Immunoglobulin Treatment of Recurrent Miscarriage:an Update of Placebo-controlled Trials

Background Immunological disturbances which may be treated with intravenous immunoglobulin (IvIg) play a significant role in the majority of patients with recurrent miscarriage (RM). The present study aimed to review the current knowledge about IvIg treatment in RM primarily based on results from published placebo controlled trials. Seven placebo controlled trials were identified comprising a total of 343 patients. The background variables, the treatment protocols and the results were extremely different between the trials. Among the patients with secondary RM, a meta analysis showed that the pooled odds ratio for live birth among IvIg treated women compared with women infused with placebo was 1.69 (95 % CI = 0.72～3.96, not significant). IvIg also seemed to be efficacious in patients with repeated second trimester intrauterine fetal deaths. A new big placebo controlled trial should be conducted which focus on RM patients with secondary RM or recurrent second trimester fetal deaths. Sufficient IvIg doses should be given with optimal time intervals.

Antimicrobial therapy using sulfamethoxazole trimethoprim for Kawasaki disease patients unresponsive to intravenous immunoglobulin

Our previous study suggested that the production of superantigens and heat-shock protein 60 by small intestinal bacteria might play a role in Kawasaki disease (KD). We demonstrated that they were all resistant to commonly used antibiotics, except for sulamethoxazole trimethoprim (SMX-TMP). We used SMX-TMP for 7 cases of KD that were unresponsive to intravenous immunoglobulin (IVIG) and studied the antipyretic potency of this treatment. In 6 out of the 7 cases, we demonstrated that antipyretic potency was observed without side effects within 2 days of the initial administration. Antimicrobial therapy using SMX-TMP might represent a novel strategy for cases of KD that are unresponsive to IVIG.

A successful birth of severe secondary recurrent miscarriage case after a decline of phosphatidylserine-dependent anti-prothrombin antibody by intravenous immunoglobulin administration

A 33 years old woman was referred to our hospital since her sixth pregnancy had been revealed. In fact, at 19 years of age she had diagnosed as having systemic lupus erythematosus without organ failure. In addition, she had a past history of uncontrollable severe pregnancy-induced hypertension occurred during the second pregnancy, resulting in extremely premature delivery and following postpartum HELLP syndrome. It was so severe that we employed administration of dexamethasone and plasma exchange to ameliorate a life-threatening situation. In the course of her recovery it was revealed that she had been complicated with antiphospholipid antibodies, and at the same time we observed that phosphatidylserine-dependent anti-prothrombin antibody IgG levels were declining as her condition was getting better. There-after, she became pregnant three times, but all pregnancies ended in miscarriage despite administration of prednisolone and anticoagulant therapy. Therefore, we realized that her recurrent miscarriages could not be prevented with generally acceptable therapies, so we tried intravenous immunoglobulin shortly after fetal heart beats were detected. In fact, her sixth pregnancy was going well, but we had to terminate it at the 35th week of gestation due to the onset of HELLP syndrome-like condition. However, she could achieve an almost intact pregnancy outcome without neonatal complications or persistently worsening postpartum HELLP syndrome-like condition. Considering the etiologic relation overlapping between systemic lupus erythematosus, antiphospholipid syndrome and recurrent miscarriage, intravenous immunoglobulin can be one of the treatment options for severe secondary recurrent miscarriage, although the evidence of the treatment is always certain. In addition, a decline of phosphatidylserine-dependent anti-prothrombin antibody IgG levels we observed in this case may represent its therapeutic immunomodulatory effects.

Haemolytic Anaemia Following High Dose Intravenous Immunoglobulin Treatment for Epidermolysis Bullosa Acquisita

Background: Epidermolysis bullosa aquisita (EBA) is a severe acquired blistering skin disease that is often resistant to prednisolone but can respond well to intravenous immunoglobulin infusion (IVIg). Main Observations: We describe the case of a 35 years old male patient with EBA who developed clinically significant haemolytic anaemia with a drop in Hb from 15.3 g/dL to a nadir of 8.4 g/dL within 5 days post IVIg infusion. The patient was blood group A and the IVIg batch was found to have a high titre of anti-A immunoglobulin. Conclusions: IVIg is an effective treatment for EBA. Haemolysis associated with IVIg has not previously been reported in the dermatology literature but review of data from other specialties shows that the problem is well recognised. Dermatologists using IVIg should be aware of this potential complication and patients should be consented appropriately and warned about this potential side effect.

川崎病患儿静脉注射免疫球蛋白抵抗的影响因素评估及IVIGR风险预测模型构建

目的 探究川崎病(KD)患儿静脉注射免疫球蛋白抵抗(IVIGR)的影响因素,并构建IVIGR预测模型,为KD患儿风险分层护理提供依据。方法 纳入2020年4月至2023年4月在嘉兴市第二医院诊治的KD患儿为研究对象。根据KD患儿是否发生IVIGR分为IVIGR组和非IVIGR组。采用逐步多因素Logistic回归探究KD患儿发生IVIGR的独立影响因素,构建KD患儿IVIGR预测模型。采用受试者工作特征曲线(ROC)、校准曲线和决策曲线评估IVIGR预测模型的预测能力、校准能力和临床净获益。结果 研究共纳入120例KD患儿,IVIG组22例,非IVIGR组98例。多因素Logistic回归结果显示,红细胞压积、总胆红素、乳酸脱氢酶和C-反应蛋白/白蛋白比值是KD患儿发生IVIGR的独立影响因素(P <0.05)。建立的KD患儿IVIGR风险预测模型ROC曲线下面积为0.858,具有良好的预测能力、校准能力和临床净获益。结论 IVIGR风险预测模型可用于KD患儿发生静脉注射IVIGR的预测,是实现风险分级护理的简单实用的工具。

A Systematic Review Incorporating Meta-Analysis on the Effectiveness of Intravenous Immunoglobulin Versus Corticosteroids in the Treatment of Pediatric Myocarditis

Background:Concerns have been raised about the efficacy of intravenous immunoglobulin and corticosteroids in pediatric myocarditis;however,the relationship between the risk and efficacy of these two therapies in children with myocarditis varies.Methods:A systematic review on seventeen studies was conducted in July 2020,which included 1,960 subjects at the baseline,with 788 receiving intravenous immunoglobulin and 142 receiving corticosteroids.The mean difference(MD)or odds ratio(OR)with 95%confidence intervals(Cis)was calculated to assess the prognostic role of both treatments using dichotomous and continuous methods with random or fixed-effect models.Results:The use of intravenous immunoglobulin was significantly associated with a lower mortality rate or heart transplantation in children with myocarditis(OR,0.55;95%CI,0.40-0.77,^<0.001)compared with the control group.However,corticosteroids were not significantly associated with the same parameters(OR,0.72;95% CI,0.31-1.63,p=0.43).The use of intravenous immunoglobulin was not significantly related to improving left ventricular ejection in children with myocarditis(OR,2.30;95% CI,-9.65-14.25,p=0.71)and so were corticosteroids(MD,5.17;95% CI,-0.26-10.60,p=0.06).Conclusion:The use of intravenous immunoglobulin might have an independent risk relationship with a lower mortality rate or heart transplantation and is recommended in children with myocarditis to prevent complications.

Impact of hepatitis B immunoglobulin mode of administration on treatment experiences of patients after liver transplantation: Results from an online survey

BACKGROUND Hepatitis B immunoglobulin(HBIG)in combination with a potent nucleos(t)ide analog is considered the standard of care for prophylaxis against hepatitis B virus(HBV)reinfection after liver transplantation for HBV-associated disease.AIM To evaluate patients’satisfaction,preferences,and requirements for subcutaneous(SC),intramuscular(IM),and intravenous(IV)HBIG treatments.METHODS A self-completion,cross-sectional,online,22-question survey was conducted to examine perceptions and satisfaction with current HBIG treatment in adults receiving HBIG treatment following liver transplantation for HBV-associated disease in France,Italy,and Turkey.Hypothetical HBIG products with different administration modes were evaluated using target product profile assessment and a conjoint(trade-off)exercise.RESULTS Ninety patients were enrolled;32%,17%,and 51%were SC,IM,and IV HBIG users,respectively.Mean duration of treatment was 36.2 months.SC HBIG had the least negative impact on emotional well-being and social life and was perceived as the most convenient,easiest to administer,least painful,and had the highest self-rating of treatment compliance.More IM HBIG users than SC or IV HBIG users reported that administration frequency was excessive(67%,28%,and 28%,respectively).In the target product profile assessment,76%of patients were likely to use hypothetical SC HBIG.In the conjoint exercise,administration route,frequency,and duration were key drivers of treatment preferences.CONCLUSION Ease,frequency,duration,and side effects of HBIG treatment administration were key drivers of treatment preferences,and SC HBIG appeared advantageous over IM and IV HBIG for administration ease,convenience,and pain.A hypothetical SC HBIG product elicited a favorable response.Patient demographics,personal preferences,and satisfaction with HBIG treatment modalities may influence long-term treatment compliance.

英夫利西单抗与 IVIG 治疗 IVIG 初治无效川崎病效果比较

目的比较英夫利西单抗与静脉注射免疫球蛋白(intravenous immunoglobulin, IVIG)治疗 IVIG 初治无效川崎病的效果。方法选取2013年1月至2017年10月本院儿科诊断的88例 IVIG 初治无效川崎病患儿为研究对象,其中22例患儿接受英夫利西单抗治疗(英夫利西单抗组),66例患儿追加 IVIG 治疗(IVIG复治组)。比较两组患儿持续发热时间、不同时间点的退热率、冠状动脉病变(coronary artery lesions,CALs)发生率及不良反应发生情况。结果英夫利西单抗组患儿平均持续发热时间[(16.8±2.9)小时]显著短于 IVIG 复治组[(56.3±8.6)小时](P<0.001),不同时间点退热率均显著高于 IVIG 复治组(P<0.05)。治疗后第10天,英夫利西单抗组1例患儿出现CALs,治疗后第56天恢复正常; IVIG 复治组9例患儿出现CALs,治疗后第56天病变仍存在。 IVIG 复治组1例患儿出现严重不良反应(治疗后3周川崎病复发);英夫利昔单抗组患儿便秘发生率显著低于 IVIG 复治组(P<0.05),治疗期间无一例患儿发生支气管炎; IVIG 复治组8例患儿发生支气管炎。两组患儿其他不良反应发生率比较均无显著差异(P>0.05)。结论英夫利西单抗能加速川崎病患儿退热,缩短患儿持续发热时间,且安全性良好,可有效治疗 IVIG 初治无效川崎病。

不同IVIG治疗方案对川崎病冠状动脉病变影响的多中心回顾性研究

目的探讨静脉丙种球蛋白(IVIG)的不同治疗方案对川崎病(KD)患儿发生冠状动脉病变(CAL)的影响,提出最佳的IVIG治疗建议方案。方法回顾性分析1998—2007年上海地区住院KD患儿1682例的临床资料,男1064例,女618例;发病年龄0.1～18.8岁,平均(2.57±2.33)岁。其中1533例(91.1%)使用IVIG治疗,方案包括①1g/kg×1次;②2g/kg×1次;③0.4～0.5g/kg×5次;④1g/kg×2次;⑤2g/kg×2次;⑥不规则治疗。IVIG治疗的时间窗包括:①病程1～4d;②病程5～10d;③病程>10d。结果在1533例IVIG治疗的KD患儿中,CAL总发生率为20.74%。与此相比较,CAL发生率明显降低者如下:①在病程5～10d应用IVIG治疗1g/kg×2次的KD患儿,其CAL发生率为12.06%;②病程5～10d应用1g/kg×1次者CAL发生率为15.00%;③病程1～4d应用1g/kg×1次者CAL发生率为16.28%;④病程5～10d应用2g/kg×1次者CAL发生率为16.71%。相反,以下几种情况CAL发生率明显高于CAL总发生率:①在病程10d以上应用IVIG者;②使用IVIG2g/kg×2次(因使用1次后效果不佳而再次使用);③其他不规律使用IVIG者。结论在IVIG治疗KD、减少CAL方面,以病程5～10d使用IVIG1g/kg×2次效果最佳;但考虑经济因素和大剂量IVIG潜在的风险,在病程10d以内使用IVIG1g/kg×1次亦是不错的选择。

IVIG治疗对复发性流产患者外周血NK细胞的影响

【目的】探讨静脉滴注免疫球蛋白(IVIG)治疗对复发性流产患者(RSA)外周血NK细胞的影响。【方法】研究组包括31例RSA患者,均进行静脉滴注免疫球蛋白(IVIG)治疗,于治疗前后采用流式细胞术检测患者外周血NK细胞毒性及NK细胞在所有淋巴细胞中的比例;26例未接受IVIG的RSA患者为对照组,首次检测检测NK细胞毒性及NK细胞比例后,于第10天复查上述项目。【结果】治疗前研究组NK细胞毒性为(19.7±8.7)%,NK细胞比例为(21.4±8.2)%,治疗后实验组NK细胞毒性为(13.1±3.7)%,NK细胞比例为(19.3±7.5)%;对照组第一次检测,NK细胞毒性为(20.1±7.0)%,NK细胞比例为(21.0±8.1)%,间隔10d复测,NK细胞毒性为(19.8±7.2)%,NK细胞比例为(21.2±7.7)%。研究组患者IVIG治疗前后外周血NK细胞毒性及比例显著降低,差异有统计学意义(P<0.05),而对照组前后两次外周血NK细胞毒性及比例无显著差异(P>0.05);研究组患者IVIG前后外周血NK细胞毒性改变与IVIG前后NK细胞比例改变没有明显的相关性(P>0.05)。【结论】IVIG治疗对NK细胞毒性及比例产生降调节作用。

IVIG治疗儿童重症腺病毒肺炎的临床疗效和并发症观察

目的分析静脉用丙种球蛋白（IVIG）应用于儿童重症腺病毒肺炎（SAP）的疗效及安全性。方法选择180例重症腺病毒肺炎儿童的临床资料进行回顾性分析,依据是否给予IVIG治疗分为观察组与对照1组,对两组患者治疗后的临床疗效、住院时间、发热持续时间、机械通气时间及并发症的发生情况进行对比。结果与对照组对比,观察组患儿的发热时间、住院时间及机械通气时间均显著缩短,痊愈率与好转率均升高,差异有统计学意义（P〈0.05）。其中在无效的人数中,观察组死亡3例（3.03%）,对照组死亡4例（4.94%）,两组对比差异无统计学意义（χ^2=0.01,P=0.732）;与对照组对比,观察组患儿发生胸腔积液、肺不张、中毒性脑病并发症的发生率显著降低,差异有统计学意义（P〈0.05）,两组患儿呼吸衰竭、肺功能损害的发生率差异无统计学意义（P〉0.05）。结论 IVIG治疗儿童SAP有一定的疗效,能降低并发症。

不同剂量IVIG对川崎病患儿CD_4^+/CD_8^+的影响

目的:研究不同剂量免疫球蛋白(IVIG)对川崎病急性期治疗前后CD4+/CD8+功能平衡的影响。方法:采用流式细胞仪检测A、B两组川崎病患儿治疗前及治疗后4天CD4+、CD8+的值。结果:治疗前A、B两组CD4+、CD4+、Cd8+、CD4+/CD8+无显著差异(P>0.05),治疗后B组与对照组有显著差异,A组与对照组差异无显著性;A组退热时间比B组明显缩短(P<0.01)。结论:川崎病患儿急性期,IVIG 2 g/kg一次输入对CD4+/CD8+功能失衡能迅速纠正,缩短发热时间。